NCI | Technology Transfer

Glypican 2 As A Cancer Marker And Therapeutic Target

Read more about Glypican 2 As A Cancer Marker And Therapeutic Target

Bulgaria
16864859.0
Filed on 2018-05-18

Glypican 2 As A Cancer Marker And Therapeutic Target

Read more about Glypican 2 As A Cancer Marker And Therapeutic Target

Sweden
16864859.0
Filed on 2018-05-18

Glypican 2 As A Cancer Marker And Therapeutic Target

Read more about Glypican 2 As A Cancer Marker And Therapeutic Target

Croatia
16864859.0
Filed on 2018-05-18

Glypican 2 As A Cancer Marker And Therapeutic Target

Read more about Glypican 2 As A Cancer Marker And Therapeutic Target

United Kingdom
16864859.0
Filed on 2018-05-18

Glypican 2 As A Cancer Marker And Therapeutic Target

Read more about Glypican 2 As A Cancer Marker And Therapeutic Target

Belgium
16864859.0
Filed on 2018-05-18

Glypican 2 As A Cancer Marker And Therapeutic Target

Read more about Glypican 2 As A Cancer Marker And Therapeutic Target

Denmark
16864859.0
Filed on 2018-05-18

Glypican 2 As A Cancer Marker And Therapeutic Target

Read more about Glypican 2 As A Cancer Marker And Therapeutic Target

Poland
16864859.0
Filed on 2018-05-18

Glypican 2 As A Cancer Marker And Therapeutic Target

Read more about Glypican 2 As A Cancer Marker And Therapeutic Target

Germany
16864859.0
Filed on 2018-05-18

FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS

Read more about FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS

Patent Cooperation Treaty
PCT/US2024/037349
Filed on 2024-07-10

T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY AGAINST CANCER

Read more about T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY AGAINST CANCER

European Patent
22854399.7
Filed on 2024-06-25

Subscribe to NCI